Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference

The new mini-textbook by Kamps & Hoffmann
PDF, 110 pages


  Lung Cancer

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 283 articles:
HTML format
Text format



Single Articles


    March 2020
  1. SCHULER M, Berardi R, Lim WT, de Jonge M, et al
    Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a Phase I trial.
    Ann Oncol. 2020 Mar 30. pii: S0923-7534(20)36380.
    PubMed     Text format     Abstract available


  2. PAZ-ARES L, Spira A, Raben D, Planchard D, et al
    Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial.
    Ann Oncol. 2020 Mar 21. pii: S0923-7534(20)36374.
    PubMed     Text format     Abstract available


  3. LAMBERTI G, Spurr LF, Li Y, Ricciuti B, et al
    Clinicopathological and genomic correlates of Programmed Cell Death Ligand 1 (PD-L1) expression in nonsquamous non-small cell lung cancer.
    Ann Oncol. 2020 Mar 11. pii: S0923-7534(20)36078.
    PubMed     Text format     Abstract available


  4. GAINOR JF, Rizvi H, Jimenez Aguilar E, Skoulidis F, et al
    Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression >/=50.
    Ann Oncol. 2020;31:404-411.
    PubMed     Text format     Abstract available


    February 2020
  5. PLANCHARD D, Reinmuth N, Orlov S, Fischer JR, et al
    ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer.
    Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36041.
    PubMed     Text format     Abstract available


  6. MANSFIELD AS, Kazarnowicz A, Karaseva N, Sanchez A, et al
    Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial.
    Ann Oncol. 2020;31:310-317.
    PubMed     Text format     Abstract available


  7. MAZIERES J, Cropet C, Montane L, Barlesi F, et al
    Vemurafenib in non-small-cell lung cancer patients with BRAF(V600) and BRAF(nonV600) mutations.
    Ann Oncol. 2020;31:289-294.
    PubMed     Text format     Abstract available


  8. PROS E, Saigi M, Alameda D, Gomez-Mariano G, et al
    Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors.
    Ann Oncol. 2020;31:274-282.
    PubMed     Text format     Abstract available


  9. PARK K, Vansteenkiste J, Lee KH, Pentheroudakis G, et al
    Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.
    Ann Oncol. 2020;31:191-201.
    PubMed     Text format     Abstract available


    January 2020
  10. OXNARD GR, Yang JC, Yu H, Kim SW, et al
    TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
    Ann Oncol. 2020 Jan 24. pii: S0923-7534(20)35946.
    PubMed     Text format     Abstract available


  11. CHALABI M, Cardona A, Nagarkar DR, Dhawahir Scala A, et al
    Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.
    Ann Oncol. 2020 Jan 16. pii: S0923-7534(20)35927.
    PubMed     Text format     Abstract available


  12. HAZELL SZ, Fu W, Hu C, Voong KR, et al
    Financial toxicity in lung cancer: an assessment of magnitude, perception, and impact on quality of life.
    Ann Oncol. 2020;31:96-102.
    PubMed     Text format     Abstract available


  13. DE RUYSSCHER D, Faivre-Finn C, Nackaerts K, Jordan K, et al
    Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer.
    Ann Oncol. 2020;31:41-49.
    PubMed     Text format     Abstract available


    December 2019
  14. YOSHIOKA H, Shimokawa M, Seto T, Morita S, et al
    Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell
    Ann Oncol. 2019;30:1978-1984.
    PubMed     Text format     Abstract available


  15. KIM C, Liu SV
    First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forward.
    Ann Oncol. 2019;30:1852-1855.
    PubMed     Text format    


    November 2019
  16. MOUNTZIOS G, Remon J, Novello S, Blais N, et al
    Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >/=1% by the USA Food and Drug Administration.
    Ann Oncol. 2019;30:1686-1688.
    PubMed     Text format    


    October 2019
  17. KIM C, Liu SV
    First-line EGFR TKI therapy in Non-Small Cell Lung Cancer: Looking back before leaping forward.
    Ann Oncol. 2019 Oct 15. pii: 5587761. doi: 10.1093.
    PubMed     Text format    


  18. DE VRIES R, Muller M, van der Noort V, Theelen WSME, et al
    Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath.
    Ann Oncol. 2019;30:1660-1666.
    PubMed     Text format     Abstract available


  19. AGUILAR EJ, Ricciuti B, Gainor JF, Kehl KL, et al
    Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.
    Ann Oncol. 2019;30:1653-1659.
    PubMed     Text format     Abstract available


    September 2019
  20. YOSHIOKA H, Shimokawa M, Seto T, Morita S, et al
    Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small cell
    Ann Oncol. 2019 Sep 25. pii: 5573754. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. DE VRIES R, Muller M, van der Noort V, Theelen WSME, et al
    Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath.
    Ann Oncol. 2019 Sep 17. pii: 5567488. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. MOUNTZIOS G, Remon J, Novello S, Blais N, et al
    Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small cell lung cancer with a PD-L1 expression level of >/= 1% by the U.S. Food and Drug Administration.
    Ann Oncol. 2019 Sep 3. pii: 5559466. doi: 10.1093.
    PubMed     Text format    


  23. KUDO Y, Haymaker C, Zhang J, Reuben A, et al
    Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer.
    Ann Oncol. 2019;30:1521-1530.
    PubMed     Text format     Abstract available


    August 2019
  24. WEISS JM, Csoszi T, Maglakelidze M, Hoyer RJ, et al
    Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small cell lung cancer receiving 1st-line chemotherapy: a Phase 1b/randomized Phase 2 trial.
    Ann Oncol. 2019 Aug 27. pii: 5555303. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. AGUILAR EJ, Ricciuti B, Gainor JF, Kehl KL, et al
    Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and very high PD-L1 expression.
    Ann Oncol. 2019 Aug 21. pii: 5552557. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2019
  26. KUDO Y, Haymaker C, Zhang J, Reuben A, et al
    Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small cell lung cancer.
    Ann Oncol. 2019 Jul 8. pii: 5529670. doi: 10.1093.
    PubMed     Text format     Abstract available


  27. CHAMPIAT S, Besse B, Marabelle A
    Hyperprogression during immunotherapy: do we really want to know?
    Ann Oncol. 2019;30:1028-1031.
    PubMed     Text format    


  28. TAMMINGA M, Groen HJM
    Circulating tumor cells are prognostic in SCLC, but still lack clinical application.
    Ann Oncol. 2019;30:1031-1033.
    PubMed     Text format    


  29. PASTORINO U, Silva M, Sestini S, Sabia F, et al
    Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy.
    Ann Oncol. 2019;30:1162-1169.
    PubMed     Text format     Abstract available


  30. KELLY RJ, Shepherd FA, Krivoshik A, Jie F, et al
    A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.
    Ann Oncol. 2019;30:1127-1133.
    PubMed     Text format     Abstract available


  31. SHAW AT, Riely GJ, Bang YJ, Kim DW, et al
    Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
    Ann Oncol. 2019;30:1121-1126.
    PubMed     Text format     Abstract available


  32. TAY RY, Fernandez-Gutierrez F, Foy V, Burns K, et al
    Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial.
    Ann Oncol. 2019;30:1114-1120.
    PubMed     Text format     Abstract available


  33. KIM CG, Kim KH, Pyo KH, Xin CF, et al
    Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.
    Ann Oncol. 2019;30:1104-1113.
    PubMed     Text format     Abstract available


  34. ROTA M, Pizzato M, La Vecchia C, Boffetta P, et al
    Efficacy of lung cancer screening appears to increase with prolonged intervention: results from the MILD trial and a meta-analysis.
    Ann Oncol. 2019;30:1040-1043.
    PubMed     Text format    


    June 2019
  35. FRUH M, Peters S
    EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in Non-Small Cell Lung Cancer.
    Ann Oncol. 2019 Jun 14. pii: 5518918. doi: 10.1093.
    PubMed     Text format    


  36. PASTORINO U, Silva M, Sestini S, Sabia F, et al
    Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy.
    Ann Oncol. 2019 Jun 5. pii: 5511622. doi: 10.1093.
    PubMed     Text format    


    May 2019
  37. MAZIERES J, Drilon A, Lusque A, Mhanna L, et al
    Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
    Ann Oncol. 2019 May 24. pii: 5498206. doi: 10.1093.
    PubMed     Text format     Abstract available


  38. HASTINGS K, Yu H, Wei W, Sanchez-Vega F, et al
    EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer.
    Ann Oncol. 2019 May 14. pii: 5488949. doi: 10.1093.
    PubMed     Text format     Abstract available


  39. KELLY RJ, Shepherd FA, Krivoshik A, Jie F, et al
    A Phase 3, Randomized, Open-label Study of ASP8273 Versus Erlotinib or Gefitinib in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer.
    Ann Oncol. 2019 May 9. pii: 5487410. doi: 10.1093.
    PubMed     Text format     Abstract available


  40. ROTA M, Pizzato M, La Vecchia C, Boffetta P, et al
    Efficacy of lung cancer screening appears to increase with prolonged intervention: results from the MILD trial and a meta-analysis.
    Ann Oncol. 2019 May 2. pii: 5482568. doi: 10.1093.
    PubMed     Text format    


  41. PLANCHARD D, Popat S, Kerr K, Novello S, et al
    Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".
    Ann Oncol. 2019;30:863-870.
    PubMed     Text format    


  42. RICORDEL C, Friboulet L, Facchinetti F, Soria JC, et al
    Correction to: "Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer".
    Ann Oncol. 2019;30:858.
    PubMed     Text format    


  43. BLUMENTHAL GM, Gong Y, Kehl K, Mishra-Kalyani P, et al
    Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer.
    Ann Oncol. 2019;30:830-838.
    PubMed     Text format     Abstract available


    April 2019
  44. TAY RY, Fernandez-Gutierrez F, Foy V, Burns K, et al
    Prognostic value of circulating tumour cells in limited-stage small cell lung cancer: analysis of the concurrent ONce-daily versus twice-daily RadioTherapy (CONVERT) randomised controlled trial.
    Ann Oncol. 2019 Apr 24. pii: 5479461. doi: 10.1093.
    PubMed     Text format     Abstract available


  45. SHAW AT, Riely GJ, Bang YJ, Kim DW, et al
    Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
    Ann Oncol. 2019 Apr 13. pii: 5448502. doi: 10.1093.
    PubMed     Text format     Abstract available


  46. KIM CG, Kim KH, Pyo KH, Xin CF, et al
    Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.
    Ann Oncol. 2019 Apr 12. pii: 5448854. doi: 10.1093.
    PubMed     Text format     Abstract available


  47. PASTORINO U, Silva M, Sestini S, Sabia F, et al
    Prolonged Lung Cancer Screening Reduced 10-year Mortality in the MILD Trial.
    Ann Oncol. 2019 Apr 1. pii: 5425325. doi: 10.1093.
    PubMed     Text format     Abstract available


  48. WIESWEG M, Mairinger F, Reis H, Goetz M, et al
    Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancer.
    Ann Oncol. 2019;30:655-657.
    PubMed     Text format    


  49. BONANNO L, Zulato E, Attili I, Pavan A, et al
    Potentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy.
    Ann Oncol. 2019;30 Suppl 2:ii9.
    PubMed     Text format    


  50. JUAN VIDAL OJ, Simarro J, Lorente Estelles D, Perez-Simo G, et al
    Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1(st) or 2(nd) generation EGFR tyrosine kinase inhibitors (TKIs).
    Ann Oncol. 2019;30 Suppl 2:ii9-ii10.
    PubMed     Text format    


  51. OWONIKOKO TK, Kim HR, Govindan R, Ready N, et al
    Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, r
    Ann Oncol. 2019;30 Suppl 2:ii77.
    PubMed     Text format    


  52. THOTTIAN AGF, Babu GK, Dasappa L, Jacob LA, et al
    Evaluation of safety and efficacy of minocycline combined with tyrosine kinase inhibitors in patients of EGFR mutated metastatic lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii76.
    PubMed     Text format    


  53. BUNTZEL J, Heinz J, Rover C, Bleckmann A, et al
    Sarcopenia as prognostic factor in lung cancer patients: A systematic review and meta-analysis.
    Ann Oncol. 2019;30 Suppl 2:ii76.
    PubMed     Text format    


  54. KIRITA K, Udagawa H, Matsumoto S, Yoh K, et al
    Feasibility and utility of transbronchial cryobiopsy in primary lung cancer: Prospective, single arm study.
    Ann Oncol. 2019;30 Suppl 2:ii76.
    PubMed     Text format    


  55. LEE SC, Kwak S, Park MS, Kim YS, et al
    Diagnostic value of concomitant use of radial probe endobronchial ultrasound with guide sheath and transbronchial biopsy in lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii75.
    PubMed     Text format    


  56. CIPRIANO E, Tavares A, Soares A, Estevinho F, et al
    Non-small cell lung cancer in the elderly: A retrospective study comparing first-line treatment with single-agent vs combination chemotherapy vs tyrosine kinase inhibitor.
    Ann Oncol. 2019;30 Suppl 2:ii75.
    PubMed     Text format    


  57. TSIOUPROU I, Tsartsianidou V, Papaemmanouil S, Pastelli N, et al
    Implementation of PD-L1 analysis among patients with non-small cell lung cancer in a single center.
    Ann Oncol. 2019;30 Suppl 2:ii75.
    PubMed     Text format    


  58. NAISH P, Purdy E
    Information for lung cancer patients and their caregivers: A systematic analysis of the online landscape.
    Ann Oncol. 2019;30 Suppl 2:ii74.
    PubMed     Text format    


  59. GODARA SK, Beniwal SK
    Psychosocial and financial impact on family of lung cancer patients: A cancer research center experience.
    Ann Oncol. 2019;30 Suppl 2:ii74.
    PubMed     Text format    


  60. LEVENTAKOS K, Helgeson J, Mansfield AS, Deering E, et al
    Implementation of artificial intelligence (AI) for lung cancer clinical trial matching in a tertiary cancer center.
    Ann Oncol. 2019;30 Suppl 2:ii74.
    PubMed     Text format    


  61. MEHTA M, Gondi V, Ahluwalia M, Brown P, et al
    Phase III METIS study: Tumor treating fields (150 kHz) and radiosurgery for supra- and/or infratentorial brain metastases (1-10) from non-small cell lung cancer (NSCLC).
    Ann Oncol. 2019;30 Suppl 2:ii70-ii71.
    PubMed     Text format    


  62. LINDSAY CR, Blackhall FH, Carmel A, Gazzaniga P, et al
    EPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii7.
    PubMed     Text format    


  63. DUMOULIN D, de Goeje P, Poncin M, Bezemer K, et al
    Paclitaxel/ carboplatin/ bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors.
    Ann Oncol. 2019;30 Suppl 2:ii7.
    PubMed     Text format    


  64. FERRARA R, Naigeon M, Auclin E, Duchemann B, et al
    Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts).
    Ann Oncol. 2019;30 Suppl 2:ii7-ii8.
    PubMed     Text format    


  65. RANISZEWSKA A, Rutkowska E, Sokolowski R, Domagala-Kulawik J, et al
    Characterization and potential role of PD-L1 positive lung cancer stem cells in lymph nodes metastasis.
    Ann Oncol. 2019;30 Suppl 2:ii69.
    PubMed     Text format    


  66. GELSOMINO F, Tiseo M, Boni L, Cavanna L, et al
    An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy: EDEN trial.
    Ann Oncol. 2019;30 Suppl 2:ii67-ii68.
    PubMed     Text format    


  67. PAZ-ARES L, Senan S, Planchard D, Wang L, et al
    RATIONALE 001: Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC).
    Ann Oncol. 2019;30 Suppl 2:ii67.
    PubMed     Text format    


  68. PAIK P, Cortot A, Felip E, Sakai H, et al
    A phase II trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study.
    Ann Oncol. 2019;30 Suppl 2:ii66.
    PubMed     Text format    


  69. SHIMOKAWA M, Nosaki K, Seto T, Ohashi K, et al
    Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study.
    Ann Oncol. 2019;30 Suppl 2:ii66.
    PubMed     Text format    


  70. PLANCHARD D, Li BT, Murakami H, Shiga R, et al
    A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii66-ii67.
    PubMed     Text format    


  71. SPICER J, Provencio M, Garrido Lopez P, Bosch-Barrera J, et al
    An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii65-ii66.
    PubMed     Text format    


  72. FRUEH M, Rahma OE, Pachynski RK, Mazieres J, et al
    Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice.
    Ann Oncol. 2019;30 Suppl 2:ii65.
    PubMed     Text format    


  73. ABDULLA DS, Ruge M, Scheffler M, Nogova L, et al
    Feasibility of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET for treatment monitoring of brain metastases in lung cancer patients.
    Ann Oncol. 2019;30 Suppl 2:ii64-ii65.
    PubMed     Text format    


  74. ALTINI M, Massa I, Balzi W, Gentili N, et al
    Real-world treatment patterns for metastatic non-small cell lung cancer at IRST Italy.
    Ann Oncol. 2019;30 Suppl 2:ii63-ii64.
    PubMed     Text format    


  75. MARTINEZ KAREAGA M, Urbieta-Macazaga N, Sanchez-Vieco C, Tomas-Lopez L, et al
    Permanent pleural catheter (PPC) for malignant pleural effusion (PE) in advanced non-small cell lung cancer (NSCLC).
    Ann Oncol. 2019;30 Suppl 2:ii63.
    PubMed     Text format    


  76. HAN B, Li K, Chu T, Bi M, et al
    A multi-center, randomized, double-blind, parallel, two-group phase III clinical study on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in the first-line treatment of non-squamous non-small cell lung c
    Ann Oncol. 2019;30 Suppl 2:ii62.
    PubMed     Text format    


  77. NIE W, Xu MD, Gan L, Zhang Y, et al
    Advanced non-small cell lung cancer patients with low tumor mutation burden might derive benefit from anti-programmed cell death (PD)-1 and anti-programmed deathligand 1 (PD-L1) blockade.
    Ann Oncol. 2019;30 Suppl 2:ii62.
    PubMed     Text format    


  78. RAPOPORT BL, Vorobiof DA, Langenhoven L, Hall JM, et al
    Prognostic significance of neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small cell lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii61.
    PubMed     Text format    


  79. ROUNIS K, Papadaki C, Makrakis D, Monastirioti A, et al
    Correlation of various clinical, imaging and laboratory parameters with outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): Results from a prospective, observational, single institut
    Ann Oncol. 2019;30 Suppl 2:ii61.
    PubMed     Text format    


  80. CORRAL DE LA FUENTE E, Barquin Garcia A, Saavedra Serrano C, Olmedo Garcia ME, et al
    Benefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly patients (EP).
    Ann Oncol. 2019;30 Suppl 2:ii61-ii62.
    PubMed     Text format    


  81. DI NOIA V, D'Argento E, Vita E, Ferrara M, et al
    Monitoring of blood serum amyloid (SAA) to predict outcome of first-line pembrolizumab (P) in patients (pts) with advanced non-small cell lung cancer (ANSCLC).
    Ann Oncol. 2019;30 Suppl 2:ii60.
    PubMed     Text format    


  82. FAEHLING M, Schwenk B, Kopp M, Fallscheer S, et al
    Immuno-oncological treatment and tumor load in non-small cell lung cancer (NSCLC): Case-control analysis of overall survival (OS) in routine clinical practice.
    Ann Oncol. 2019;30 Suppl 2:ii60.
    PubMed     Text format    


  83. LANDRE T, Des Guetz G, Vergnenegre A, Chouaid C, et al
    Clinical benefit of anti PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment in advanced non-small cell lung cancer: A meta-analysis.
    Ann Oncol. 2019;30 Suppl 2:ii60.
    PubMed     Text format    


  84. JERMANN P, Alborelli I, Leonards K, Rothschild SI, et al
    Tumor mutational burden assessed by a targeted NGS assay predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii59.
    PubMed     Text format    


  85. PRELAJ A, Lo Russo G, Signorelli D, Ferrara R, et al
    EPSILoN score: Validation cohort of a prognostic score in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy.
    Ann Oncol. 2019;30 Suppl 2:ii59.
    PubMed     Text format    


  86. PRELAJ A, Rebuzzi SE, Pizzutilo P, Bilancia M, et al
    Peripheral blood biomarkers as prognostic factors for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients.
    Ann Oncol. 2019;30 Suppl 2:ii58.
    PubMed     Text format    


  87. PAVAN A, Calvetti L, Dal Maso A, Attili I, et al
    Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC): Platelet-to-lymphocyte ratio (PLR) predicts the risk of development and relapse.
    Ann Oncol. 2019;30 Suppl 2:ii58-ii59.
    PubMed     Text format    


  88. SCHETT A, Rothschild SI, Mauti LA, Schmid S, et al
    Prognostic impact of the use of antibiotics in patients with advanced non-small cell lung cancer (NSCLC) receiving PD-(L)1 targeting monoclonal antibodies.
    Ann Oncol. 2019;30 Suppl 2:ii58.
    PubMed     Text format    


  89. SAAVEDRA SERRANO C, Barquin Garcia A, Corral de la Fuente E, Serrano Domingo JJ, et al
    Association of immune-related adverse events (irAEs) and immunotherapy (IT) benefit in advanced non-small cell lung cancer (NSCLC).
    Ann Oncol. 2019;30 Suppl 2:ii57-ii58.
    PubMed     Text format    


  90. HORINOUCHI H, Nogami N, Saka H, Nishio M, et al
    Safety and tolerability of pembrolizumab or placebo plus pemetrexed and platinum as first-line therapy in Japanese patients (PTS) with metastatic non-squamous non-small cell lung cancer (NSCLC) enrolled in the phase III KEYNOTE-189 study.
    Ann Oncol. 2019;30 Suppl 2:ii56-ii57.
    PubMed     Text format    


  91. GALLI G, Proto C, Signorelli D, Imbimbo M, et al
    Characterization of patients with metastatic non-small cell lung cancer obtaining long term benefit from immunotherapy.
    Ann Oncol. 2019;30 Suppl 2:ii56.
    PubMed     Text format    


  92. SCHEFFLER M, Frank R, Ihle MA, Abdulla DS, et al
    Impact on KRAS-subtypes and TP53 mutations on the prognostic value of KRAS/KEAP1 comutations in non-small cell lung cancer (NSCLC).
    Ann Oncol. 2019;30 Suppl 2:ii55.
    PubMed     Text format    


  93. KHO CYX, Lim DW, Tan DSW, Tan WL, et al
    Clinicopathological characteristics and outcome of advanced ROS1-positive non-small cell lung cancer in Asian patients.
    Ann Oncol. 2019;30 Suppl 2:ii54.
    PubMed     Text format    


  94. PASSARO A, Prelaj A, Spitaleri G, Del Signore E, et al
    Clinical and treatment features associated with improved 5-year survival rate in ALK-positive lung cancer treated with ALK-TKIs.
    Ann Oncol. 2019;30 Suppl 2:ii54.
    PubMed     Text format    


  95. ZHAO Y, Zhang B, Zhang Y, Wang S, et al
    Role of radiotherapy in management of brain metastases in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC): A single-center retrospective study.
    Ann Oncol. 2019;30 Suppl 2:ii54.
    PubMed     Text format    


  96. ANGELATS L, Garcia Campelo MR, Bernabe Caro R, Arriola Aperribay E, et al
    Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p).
    Ann Oncol. 2019;30 Suppl 2:ii53.
    PubMed     Text format    


  97. PAN X, Lin MM, Yin Y, Hou P, et al
    Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United States.
    Ann Oncol. 2019;30 Suppl 2:ii52-ii53.
    PubMed     Text format    


  98. ZHANG Y, Liu T, Zeng Y, Zhu J, et al
    PD-L1 confers primary resistance to EGFR-TKI in EGFR mutant non-small cell lung cancer via inducing EMT phenotype.
    Ann Oncol. 2019;30 Suppl 2:ii52.
    PubMed     Text format    


  99. KRPINA K, Budimir B, Kukulj S, Marusic A, et al
    Correlation of molecular status and anatomic sites of metastases at diagnosis of EGFR positive non-small cell lung cancer (NSCLC): A single institution experience.
    Ann Oncol. 2019;30 Suppl 2:ii52.
    PubMed     Text format    


  100. FASSUNKE J, Heydt C, Michels S, Van Veggel B, et al
    New insights into acquired resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor therapy in lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii51.
    PubMed     Text format    


  101. SOW ML, El Yacoubi H, Moukafih B, Balde S, et al
    Frequency and types of EGFR mutation in Moroccan patients with non-small cell lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii50.
    PubMed     Text format    


  102. ZHANG J, Zhou ZS, Su YC, Yu TQ, et al
    Relationship of clinicopathological characteristics, EGFR genotyping and prognosis in non-small cell lung cancer patients with malignant pleural effusion.
    Ann Oncol. 2019;30 Suppl 2:ii50.
    PubMed     Text format    


  103. LIAN Z, Du W, Zhu J, Zeng Y, et al
    Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii50.
    PubMed     Text format    


  104. JIA H, Qi H, Peng J, Li M, et al
    FOXP3Delta3, the major isoform of FOXP3, promotes proliferation, migration, and invasion in non-small cell lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii5-ii6.
    PubMed     Text format    


  105. ZHU Y, Xu C, Wang W, Zhang Q, et al
    The characteristics of MET exon 14 skipping mutations in Chinese non-small cell lung cancer: A retrospective analysis.
    Ann Oncol. 2019;30 Suppl 2:ii5.
    PubMed     Text format    


  106. KOKKOTOU E, Rapti V, Grapsa D, Bakakos P, et al
    Immunohistochemical expression of PD-L1 in early and late stage non-small cell lung cancer: Correlation with clinicopathological and molecular features.
    Ann Oncol. 2019;30 Suppl 2:ii5.
    PubMed     Text format    


  107. CORDOBA ORTEGA JF, Salud A, Morales S, Veas J, et al
    TTF1 status in non-small cell lung cancer adenocarcinoma: A prognostic factor.
    Ann Oncol. 2019;30 Suppl 2:ii5.
    PubMed     Text format    


  108. LI J, Nickens DJ, Wilner K, Tan W, et al
    The effect of proton pump inhibitors (PPI) on dacomitinib (DACO) pharmacokinetics and efficacy in non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutation.
    Ann Oncol. 2019;30 Suppl 2:ii49.
    PubMed     Text format    


  109. SHARMA D, Slevin F, Clarke K, Franks K, et al
    Regional retrospective analysis of outcomes of EGFR mutated non-squamous non-small cell lung cancer (NSCLC) patients in West Yorkshire.
    Ann Oncol. 2019;30 Suppl 2:ii49.
    PubMed     Text format    


  110. BARLESI F, Drilon A, De Braud F, Cho BC, et al
    Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2.
    Ann Oncol. 2019;30 Suppl 2:ii48-ii49.
    PubMed     Text format    


  111. SRINIVASALU VK, Subramaniam N, Raghuram S, Kolathu S, et al
    Thromboembolic events in advanced non-small cell lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii48-ii49.
    PubMed     Text format    


  112. SHAW A, Riely GJ, Bang YJ, Kim DW, et al
    Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001.
    Ann Oncol. 2019;30 Suppl 2:ii48-ii49.
    PubMed     Text format    


  113. XU C, Wang W, Zhu Y, Yu Z, et al
    Potential resistance mechanisms using next generation sequencing from Chinese EGFR T790M+ non-small cell lung cancer patients with primary resistance to osimertinib: A multicenter study.
    Ann Oncol. 2019;30 Suppl 2:ii48.
    PubMed     Text format    


  114. DRILON A, Kummar S, Moreno V, Patel J, et al
    Activity of larotrectinib in TRK fusion lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii48-ii49.
    PubMed     Text format    


  115. PAZ-ARES L, Doebele RC, Farago AF, Liu SV, et al
    Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001.
    Ann Oncol. 2019;30 Suppl 2:ii48-ii49.
    PubMed     Text format    


  116. ALDEA M, Hendriks L, Mezquita L, Remon-Masip J, et al
    Plasma circulating tumor DNA analysis (ctDNA) for molecular alteration detection in advanced non-small cell lung cancer (NSCLC) patients (pts) with isolated central nervous system (CNS) metastases (mts).
    Ann Oncol. 2019;30 Suppl 2:ii48.
    PubMed     Text format    


  117. HORN L, Whisenant JG, Wakelee H, Reckamp KL, et al
    Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC).
    Ann Oncol. 2019;30 Suppl 2:ii48.
    PubMed     Text format    


  118. NIE W, Qian J, Han BH
    Blood tumor mutational burden as a predictor of clinical benefit in non-small cell lung cancer patients treated with docetaxel: Secondary analysis of the OAK and POPLAR randomized clinical trials.
    Ann Oncol. 2019;30 Suppl 2:ii48.
    PubMed     Text format    


  119. PEROL M, Dixmier A, Barlesi F, Debieuvre D, et al
    Health-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study.
    Ann Oncol. 2019;30 Suppl 2:ii48.
    PubMed     Text format    


  120. ROEPER J, Lueers AC, Falk M, Schatz S, et al
    Risk of not receiving second-line therapy is high in EGFR mt+ patients: Real-world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients.
    Ann Oncol. 2019;30 Suppl 2:ii48.
    PubMed     Text format    


  121. YANG JC, Ramalingam SS, Lee CK, Kurata T, et al
    Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts.
    Ann Oncol. 2019;30 Suppl 2:ii48.
    PubMed     Text format    


  122. SHEMESH R, Gorzalczany Y, Sagi-Eisenberg R, Geva S, et al
    The micro-environmental cross talk between mast cells and lung cancer cells through cell-to-cell contact.
    Ann Oncol. 2019;30 Suppl 2:ii4.
    PubMed     Text format    


  123. ZHANG Q, Xu C, Wang W, Zhuang W, et al
    Clinicopathologic characteristics of patients with TP63 mutations in Chinese non-small cell lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii4.
    PubMed     Text format    


  124. LIANG L, Hui K, Hu C, Wen Y, et al
    Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
    Ann Oncol. 2019;30 Suppl 2:ii4.
    PubMed     Text format    


  125. ROITBERG FSR, Neffa MFBV, Bonadio RRCC, Harada G, et al
    Efficacy and safety of adjuvant chemotherapy in lung cancer: Real-world evidence.
    Ann Oncol. 2019;30 Suppl 2:ii37.
    PubMed     Text format    


  126. EZE C, Taugner J, Kasmann L, Roengvoraphoj O, et al
    Pattern of first-site failure and salvage treatment in patients with inoperable stage III non-small cell lung cancer after chemoradiotherapy.
    Ann Oncol. 2019;30 Suppl 2:ii36.
    PubMed     Text format    


  127. TAUGNER J, Kasmann L, Eze C, Dantes M, et al
    Heterogeneity score in inoperable stage III non-small cell lung cancer patients treated with definitive chemoradiotherapy: A single centre analysis.
    Ann Oncol. 2019;30 Suppl 2:ii35.
    PubMed     Text format    


  128. HARBEGUE K, Mejri N, El Benna H, Labidi S, et al
    Challenges in the management of stage III non-small cell lung cancer (NSCLC) within multidisciplinary team (MDT): A lung cancer center experience.
    Ann Oncol. 2019;30 Suppl 2:ii35.
    PubMed     Text format    


  129. GIRARD N, Perol M, Simon G, Audigier Valette C, et al
    Real-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database.
    Ann Oncol. 2019;30 Suppl 2:ii34.
    PubMed     Text format    


  130. GREEN A, Olsen KE, Bliddal M, Christensen HN, et al
    Treatment patterns and long-term survival for unresected stage III non-small cell lung cancer patients: A nationwide register study in Denmark.
    Ann Oncol. 2019;30 Suppl 2:ii34.
    PubMed     Text format    


  131. PRELAJ A, Rebuzzi SE, Pizzutilo P, Bilancia M, et al
    Time-series of peripheral blood biomarkers as biomarkers for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients.
    Ann Oncol. 2019;30 Suppl 2:ii34.
    PubMed     Text format    


  132. CREELAN BC, Yeh T, Kim SW, Nogami N, et al
    Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations.
    Ann Oncol. 2019;30 Suppl 2:ii31-ii32.
    PubMed     Text format    


  133. PETERS S, Kim AW, Solomon B, Gandara DR, et al
    IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy.
    Ann Oncol. 2019;30 Suppl 2:ii30.
    PubMed     Text format    


  134. ROCHA P, Rodrigo M, Moliner L, Hardy-Werbin M, et al
    Higher PD-L1 expression correlates with lymphocyte infiltration in early non-small cell lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii30.
    PubMed     Text format    


  135. CORDOBA ORTEGA JF, Salud A, Morales S, Veas J, et al
    High blood platelets levels (BPL): A prognostic factor in patients with early or locally advanced non-small cell lung cancer (NSCLC).
    Ann Oncol. 2019;30 Suppl 2:ii30.
    PubMed     Text format    


  136. DROSSLEROVA M, Sterclova M, Vasakova M, Taskova A, et al
    Role of chemokines in resectable non-small cell lung cancer (NSCLC).
    Ann Oncol. 2019;30 Suppl 2:ii3.
    PubMed     Text format    


  137. WANG W, Xu C, Zhang Q, Zhuang W, et al
    The prevalence and prognostic significance of JAK2 mutation subtypes in non-small cell lung cancer from Chinese populations.
    Ann Oncol. 2019;30 Suppl 2:ii3-ii4.
    PubMed     Text format    


  138. GE H, Chen X, Ruan L, Gao Q, et al
    Clinical validation of an NGS-based assay for detecting multiple genomic alterations in Chinese patients with non-small cell lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii3.
    PubMed     Text format    


  139. PIROGOV SS, Telegina L, Sokolov V, Karmakova T, et al
    Endobronchial surgery and photodynamic therapy for early central lung cancer treatment.
    Ann Oncol. 2019;30 Suppl 2:ii29.
    PubMed     Text format    


  140. GAGLIASSO M, Cartia CF, Maraschi A, Rapana R, et al
    The prognostic impact of the international association for the study of lung cancer (IASLC) definitions on completeness of surgical resection for non-small cell lung cancer (NSCLC).
    Ann Oncol. 2019;30 Suppl 2:ii29.
    PubMed     Text format    


  141. CHEN X, Deng Y, Shi Y
    Tissue microarray analysis on prognostic value of coexpression of RUNX3 and trimethylated histone H3 lysine 27 in surgically resected patients with stage I non-small cell lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii29.
    PubMed     Text format    


  142. SUN F, Banfill K, Lilley J, Wheller B, et al
    Multi-centre analysis of cardiac events following radical radiotherapy for lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii27.
    PubMed     Text format    


  143. KIM H, Yoo H, Pyo H, Park HY, et al
    Impact of underlying pulmonary diseases on treatment outcomes in early stage non-small cell lung cancer treated with definitive radiotherapy.
    Ann Oncol. 2019;30 Suppl 2:ii27.
    PubMed     Text format    


  144. SENAN S, Shire N, Mak G, Yao W, et al
    ADRIATIC: A phase III trial of durvalumab +/- tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii25.
    PubMed     Text format    


  145. JAT RR, Rai RK, Jakhar SL, Beniwal SK, et al
    Experience of prophylactic cranial irradiation in extensive stage small cell lung cancer at a regional cancer center in India.
    Ann Oncol. 2019;30 Suppl 2:ii24.
    PubMed     Text format    


  146. SEBASTIAN M, Barlesi F, Califano R, Mansfield AS, et al
    Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice.
    Ann Oncol. 2019;30 Suppl 2:ii24.
    PubMed     Text format    


  147. KASMANN L, Abdo R, Taugner J, Eze C, et al
    External validation of a survival score for limited stage small cell lung cancer treated with chemoradiotherapy.
    Ann Oncol. 2019;30 Suppl 2:ii23.
    PubMed     Text format    


  148. MCSORLEY LM, Goggin CM, Elhadi N, O'Dea P, et al
    Timing of treatment with concurrent chemoradiotherapy (CRT) and impact on progression free survival (PFS) in limited stage small cell lung cancer (LSSCLC).
    Ann Oncol. 2019;30 Suppl 2:ii23-ii24.
    PubMed     Text format    


  149. YU J, Ouyang W, Hu J, Zhang J, et al
    Value of post-radiotherapy for limited stage small cell lung cancer on basis of a prognostic scoring model.
    Ann Oncol. 2019;30 Suppl 2:ii23.
    PubMed     Text format    


  150. LIU J, Zhou H, Zhang Y, Fang W, et al
    Nomogram for patients with stage I small cell lung cancer: A competing risk analysis.
    Ann Oncol. 2019;30 Suppl 2:ii22.
    PubMed     Text format    


  151. BUSHRA S, Tibdewal A, Mummudi N, Kinhikar R, et al
    Comparison of internal target volume delineation using CT datasets of four-dimensional computed tomography in lung cancer radiotherapy.
    Ann Oncol. 2019;30 Suppl 2:ii21.
    PubMed     Text format    


  152. GUNDU N, Malik PS, Khurana S, Pathy S, et al
    Non-small cell lung carcinoma (NSCLC) patients with baseline brain imaging: A prospective observational study.
    Ann Oncol. 2019;30 Suppl 2:ii20.
    PubMed     Text format    


  153. SON C
    Correlation of epidermal growth factor receptor mutation status in plasma and tissue samples of patients with lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii2.
    PubMed     Text format    


  154. WEINBERG U, Kaynan N, Voloshin Sela T, Davidi S, et al
    Immunomodulatory effects of Tumor Treating Fields (TTFields) on lung cancer models.
    Ann Oncol. 2019;30 Suppl 2:ii2-ii3.
    PubMed     Text format    


  155. LEE KA, Felix W, Jackson G
    Concordance, decision impact, and satisfaction for a computerized clinical decision support system in treatment of lung cancer patients.
    Ann Oncol. 2019;30 Suppl 2:ii19.
    PubMed     Text format    


  156. MCCANN K, Faisal W
    Invasive diagnostic investigation-related complications and its impact on treatment initiation in lung cancer patients in a rapid access lung lesion clinic in regional Australia.
    Ann Oncol. 2019;30 Suppl 2:ii19.
    PubMed     Text format    


  157. AKTER MS, Ahmed S
    Pulmonary tuberculosis: A hurdle to overcome for early lung cancer diagnosis in TB burden countries.
    Ann Oncol. 2019;30 Suppl 2:ii19.
    PubMed     Text format    


  158. LIU J, Zhou H, Zhang Y, Fang W, et al
    A Mendelian randomization study of the effects of Crohn's disease on lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii18.
    PubMed     Text format    


  159. ZHOU H, Zhang Y, Liu J, Yang Y, et al
    Education and lung cancer: A Mendelian randomisation study.
    Ann Oncol. 2019;30 Suppl 2:ii18.
    PubMed     Text format    


  160. LELEU O, Auquier MA, Chauffert B, Berna P, et al
    Baseline results from a French pilot study on lung cancer screening by CT scan: DEP KP80.
    Ann Oncol. 2019;30 Suppl 2:ii14.
    PubMed     Text format    


  161. KIM Y
    Implementation of organized lung cancer screening program in Korea.
    Ann Oncol. 2019;30 Suppl 2:ii14.
    PubMed     Text format    


  162. KUO TC, Hsiao TH, Yang PC
    The metabolic phenotypes of non-small cell lung cancer cells in association with clinical treatment strategies.
    Ann Oncol. 2019;30 Suppl 2:ii13.
    PubMed     Text format    


  163. LI CC, He Q, Liang H, He J, et al
    Diagnostic accuracy of droplet digital PCR (ddPCR) and amplification refractory mutation system PCR (ARMS-PCR) for detecting EGFR mutation in cell-free DNA of advanced lung cancer: A meta-analysis.
    Ann Oncol. 2019;30 Suppl 2:ii13.
    PubMed     Text format    


  164. LIANG L, Hu C, Wen Y, Zhuang W, et al
    High dose apatinib in the reversal of immunosuppressive tumor microenvironment for irradiation therapy in lung carcinoma.
    Ann Oncol. 2019;30 Suppl 2:ii12.
    PubMed     Text format    


  165. DIMITRAKOPOULOS FD, Antonacopoulou A, Kottorou A, Tzelepi V, et al
    Genetic variation of lymphotoxin beta receptor (LTbetaR) rs10849448 (A/G) is associated with risk for lung cancer and metastatic spread to adrenals.
    Ann Oncol. 2019;30 Suppl 2:ii12.
    PubMed     Text format    


  166. YEH YT, Wu CR, Lai JC, Huang CH, et al
    Impacts of HDAC2 inhibition on lung cancer treatment.
    Ann Oncol. 2019;30 Suppl 2:ii11.
    PubMed     Text format    


  167. DOMAGALA-KULAWIK J, Skirecki T, Dziedzic D, Polubiec-Kownacka M, et al
    Do two lungs form an integrated immune system? Learning from BALF examination in lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii10.
    PubMed     Text format    


  168. KOTSANTIS I, Economopoulou P, Psyrri A, Maratou E, et al
    Prognostic significance of IGF-1 signaling pathway in patients with advanced non-small cell lung cancer.
    Ann Oncol. 2019;30 Suppl 2:ii10.
    PubMed     Text format    


  169. KUIJPERS C, Van den Heuvel M, Overbeek L, Van Lindert A, et al
    Notable variation of molecular testing in metastatic lung cancer in the Netherlands.
    Ann Oncol. 2019;30 Suppl 2:ii1-ii2.
    PubMed     Text format    


  170. JANUSZEWSKI A, Zhang YZ, Chang WC, Laggner U, et al
    Impact of MET variants on PD-L1 expression in pleomorphic lung carcinoma.
    Ann Oncol. 2019;30 Suppl 2:ii1.
    PubMed     Text format    


    March 2019
  171. PETERS S, Reck M, Smit EF, Mok T, et al
    How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non-Small-Cell Lung Cancer.
    Ann Oncol. 2019 Mar 26. pii: 5420157. doi: 10.1093.
    PubMed     Text format     Abstract available


  172. HANNIGAN B, Ye W, Mehrotra M, Lam V, et al
    Liquid Biopsy Assay for Lung Carcinoma Using Centrifuged Supernatants from Fine Needle Aspiration Specimens.
    Ann Oncol. 2019 Mar 18. pii: 5384494. doi: 10.1093.
    PubMed     Text format     Abstract available


  173. EKMAN S
    HER2: defining a Neu target in non-small-cell lung cancer.
    Ann Oncol. 2019;30:353-355.
    PubMed     Text format    


    February 2019
  174. BLUMENTHAL GM, Gong Y, Kehl K, Mishra-Kalyani P, et al
    Analysis of Time to Treatment Discontinuation of Targeted Therapy, Immunotherapy, and Chemotherapy in clinical trials of patients with non-small cell lung cancer.
    Ann Oncol. 2019 Feb 22. pii: 5362014. doi: 10.1093.
    PubMed     Text format     Abstract available


  175. WIESWEG M, Mairinger F, Reis H, Goetz M, et al
    Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small cell lung cancer.
    Ann Oncol. 2019 Feb 11. pii: 5315508. doi: 10.1093.
    PubMed     Text format    


  176. MORABITO A
    Improving our knowledge in PD-L1 testing in lung cancer: the archival sample is 'promoted'!
    Ann Oncol. 2019 Feb 2. pii: 5306111. doi: 10.1093.
    PubMed     Text format    


  177. AMARAL SR, Casal Moura M, Carvalho J, Chaves A, et al
    6PPrognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors.
    Ann Oncol. 2019;30.
    PubMed     Text format    


  178. WANG M, Ma X
    26PTexture analysis in contrast enhanced CT: New method to predict prognosis of small cell lung cancer treated with platinum-based chemotherapy.
    Ann Oncol. 2019;30.
    PubMed     Text format    


  179. XIE Y
    35PEnhancement of high-LET radiation-induced lung cancer cell apoptosis by Antennapedia proteins (ANTP)-SmacN7.
    Ann Oncol. 2019;30.
    PubMed     Text format    


  180. BRONTE G, Puccetti M, Crino L, Bravaccini S, et al
    Epithelial-to-mesenchymal transition and EGFR status in NSCLC: the role of vimentin expression.
    Ann Oncol. 2019;30:339-340.
    PubMed     Text format    


  181. BOFFETTA P, Righi L, Ciocan C, Pelucchi C, et al
    Reply to letters to the editor by Brentisci et al. and Consonni and Mensi.
    Ann Oncol. 2019;30:341.
    PubMed     Text format    


  182. CONSONNI D, Mensi C
    Comment on the paper 'Boffetta et al. Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy. Ann Oncol 2018; 29(2): 484-489'.
    Ann Oncol. 2019;30:340-341.
    PubMed     Text format    


  183. WU YL, Planchard D, Lu S, Sun H, et al
    Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.
    Ann Oncol. 2019;30:171-210.
    PubMed     Text format     Abstract available


  184. MORABITO A
    Improving our knowledge in PD-L1 testing in lung cancer: the archival sample is 'promoted'!
    Ann Oncol. 2019;30:165-167.
    PubMed     Text format    


  185. PETERS S, Dafni U, Boyer M, De Ruysscher D, et al
    Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
    Ann Oncol. 2019;30:161-165.
    PubMed     Text format    


  186. AMARAL SR, Casal Moura M, Carvalho J, Chaves A, et al
    Prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors.
    Ann Oncol. 2019;30 Suppl 1:i3.
    PubMed     Text format    


  187. XIE Y
    Enhancement of high-LET radiation-induced lung cancer cell apoptosis by Antennapedia proteins (ANTP)-SmacN7.
    Ann Oncol. 2019;30 Suppl 1:i13.
    PubMed     Text format    


  188. WANG M, Ma X
    Texture analysis in contrast enhanced CT: New method to predict prognosis of small cell lung cancer treated with platinum-based chemotherapy.
    Ann Oncol. 2019;30 Suppl 1:i10.
    PubMed     Text format    


    January 2019
  189. ZUO H, Ueland PM, Midttun O, Tell GS, et al
    Vitamin B6 catabolism and lung cancer risk: results from the Lung Cancer Cohort Consortium (LC3).
    Ann Oncol. 2019 Jan 30. pii: 5304407. doi: 10.1093.
    PubMed     Text format     Abstract available


  190. PLANCHARD D, Popat S, Kerr K, Novello S, et al
    Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2019 Jan 30. pii: 5304567. doi: 10.1093.
    PubMed     Text format    


  191. PETERS S, Dafni U, Boyer M, De Ruysscher D, et al
    Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
    Ann Oncol. 2019 Jan 8. pii: 5280724. doi: 10.1093.
    PubMed     Text format    


  192. DE LIMA LOPES G, Aguiar P Jr
    Reply to the letter to the editor 'Response to the effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors' by Ogale.
    Ann Oncol. 2019;30:149-150.
    PubMed     Text format    


    December 2018
  193. WANG Y, Jiang T, Qin Z, Jiang J, et al
    HER2 exon 20 insertions in Non-Small Cell Lung Cancer are Sensitive to the Irreversible Pan-HER Receptor Tyrosine Kinase Inhibitor Pyrotinib.
    Ann Oncol. 2018 Dec 31. pii: 5267836. doi: 10.1093.
    PubMed     Text format     Abstract available


  194. WU YL, Planchard D, Lu S, Sun H, et al
    Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer; a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.
    Ann Oncol. 2018 Dec 28. pii: 5265324. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2018
  195. WAN Y, Liu B, Lei H, Zhang B, et al
    Nanoscale Extracellular Vesicle-Derived DNA is Superior to Circulating Cell Free DNA for Mutation Detection in Early-Stage Non-Small Cell Lung Cancer.
    Ann Oncol. 2018 Oct 18. pii: 5136413. doi: 10.1093.
    PubMed     Text format     Abstract available


  196. PLANCHARD D, Popat S, Kerr K, Novello S, et al
    Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2018;29.
    PubMed     Text format    


    September 2018
  197. GADGEEL S, Peters S, Mok T, Shaw AT, et al
    Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
    Ann Oncol. 2018 Sep 12. pii: 5095692. doi: 10.1093.
    PubMed     Text format     Abstract available


  198. TANIGUCHI Y, Takeda M, Tamiya A, Kasai T, et al
    Programmed death-ligand 1 expression in uncommon epidermal growth factor receptor mutation-positive non-small cell lung cancer.
    Ann Oncol. 2018 Sep 10. pii: 5094491. doi: 10.1093.
    PubMed     Text format    


    August 2018
  199. KRON A, Alidousty C, Scheffler M, Merkelbach-Bruse S, et al
    Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
    Ann Oncol. 2018 Aug 23. pii: 5079835. doi: 10.1093.
    PubMed     Text format     Abstract available


  200. COSTA DB
    TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer.
    Ann Oncol. 2018 Aug 23. pii: 5110095. doi: 10.1093.
    PubMed     Text format    


  201. THOMAS M, Ponce-Aix S, Navarro A, Riera-Knorrenschild J, et al
    Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: Results from the exploratory, controlled, randomized, international phase 2 IMPULSE study.
    Ann Oncol. 2018 Aug 20. pii: 5076437. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2018
  202. BASU B, Krebs MG, Sundar R, Wilson RH, et al
    Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.
    Ann Oncol. 2018 Jul 17. pii: 5055047. doi: 10.1093.
    PubMed     Text format     Abstract available


  203. SORIA JC, Ho SN, Varella-Garcia M, Iafrate AJ, et al
    Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small cell lung cancer.
    Ann Oncol. 2018 Jul 13. pii: 5053587. doi: 10.1093.
    PubMed     Text format     Abstract available


  204. COTTRELL TR, Thompson ED, Forde PM, Stein JE, et al
    Pathologic Features of Response to Neoadjuvant Anti-PD-1 in Resected Non-Small Cell Lung Carcinoma: A Proposal for Quantitative Immune-Related Pathologic Response Criteria (irPRC).
    Ann Oncol. 2018 Jul 6. pii: 5049993. doi: 10.1093.
    PubMed     Text format     Abstract available


  205. RICORDEL C, Friboulet L, Facchinetti F, Soria JC, et al
    Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.
    Ann Oncol. 2018 Jul 3. pii: 5048419. doi: 10.1093.
    PubMed     Text format    


    June 2018
  206. BONOMI PD, Gandara D, Hirsch FR, Kerr KM, et al
    Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
    Ann Oncol. 2018 Jun 14. pii: 5037893. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2018
  207. GERBER DE, Horn L, Boyer M, Sanborn R, et al
    Randomized phase 3 study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.
    Ann Oncol. 2018 May 14. pii: 4996069. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2018
  208. PINATO DJ, Kythreotou A, Mauri FA, Suardi E, et al
    Functional immune characterization of HIV-associated non-small cell lung cancer.
    Ann Oncol. 2018 Apr 20. pii: 4979448. doi: 10.1093.
    PubMed     Text format    


  209. NOVELLO S, Mazieres J, Oh IJ, de Castro J, et al
    Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.
    Ann Oncol. 2018 Apr 14. pii: 4970555. doi: 10.1093.
    PubMed     Text format     Abstract available


  210. WANG H, Agulnik J, Kasymjanova G, Wang A, et al
    Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer.
    Ann Oncol. 2018 Apr 12. pii: 4969231. doi: 10.1093.
    PubMed     Text format     Abstract available


  211. MULLER DC, Hodge AM, Fanidi A, Albanes D, et al
    No association between circulating concentrations of vitamin D and risk of lung cancer: An analysis in 20 prospective studies in the Lung Cancer Cohort Consortium (LC3).
    Ann Oncol. 2018 Apr 2. pii: 4958387. doi: 10.1093.
    PubMed     Text format     Abstract available


  212. DACIC S
    Time is up for PD-L1 testing standardization in lung cancer.
    Ann Oncol. 2018;29:791-792.
    PubMed     Text format    


    March 2018
  213. DEROSA L, Hellmann MD, Spaziano M, Halpenny D, et al
    Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small cell lung cancer.
    Ann Oncol. 2018 Mar 30. pii: 4956695. doi: 10.1093.
    PubMed     Text format     Abstract available


  214. TAO MH, Chen S, Freudenheim JL, Cauley JA, et al
    Oral bisphosphonate use and lung cancer incidence among postmenopausal women.
    Ann Oncol. 2018 Mar 29. pii: 4956655. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2018
  215. MCCOACH CE, Blumenthal GM, Zhang L, Myers A, et al
    Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.
    Ann Oncol. 2018 Feb 26. pii: 4909805. doi: 10.1093.
    PubMed     Text format    


  216. VOKES EE, Ready N, Felip E, Horn L, et al
    Nivolumab versus docetaxel in previously treated advanced non-small cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
    Ann Oncol. 2018 Feb 2. pii: 4835443. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  217. ADAM J, Le Stang N, Rouquette I, Cazes A, et al
    Multicenter French harmonization study for PD-L1 IHC testing in non-small cell lung cancer.
    Ann Oncol. 2018 Jan 16. pii: 4812668. doi: 10.1093.
    PubMed     Text format     Abstract available


  218. LI YS, Jiang BY, Yang JJ, Zhang XC, et al
    Unique Genetic Profiles from Cerebrospinal Fluid Cell-free DNA in Leptomeningeal Metastases of EGFR-mutant Non-Small Cell Lung Cancer: A New Medium of Liquid Biopsy.
    Ann Oncol. 2018 Jan 15. pii: 4810473. doi: 10.1093.
    PubMed     Text format     Abstract available


  219. LAVOLE A, Guihot A, Veyri M, Lambotte O, et al
    PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy?
    Ann Oncol. 2018 Jan 15. pii: 4810471. doi: 10.1093.
    PubMed     Text format    


  220. GUIBERT N, Hu Y, Feeney N, Kuang Y, et al
    Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.
    Ann Oncol. 2018 Jan 9. pii: 4794870. doi: 10.1093.
    PubMed     Text format     Abstract available


  221. GHORANI E, Rosenthal R, McGranahan N, Reading JL, et al
    Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma.
    Ann Oncol. 2018;29:271-279.
    PubMed     Text format     Abstract available


  222. ILIE M, Szafer-Glusman E, Hofman V, Chamorey E, et al
    Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
    Ann Oncol. 2018;29:193-199.
    PubMed     Text format     Abstract available


  223. RICORDEL C, Friboulet L, Facchinetti F, Soria JC, et al
    Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.
    Ann Oncol. 2018;29.
    PubMed     Text format     Abstract available


    December 2017
  224. KORDBACHEH T, Honeychurch J, Blackhall F, Faivre-Finn C, et al
    Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms.
    Ann Oncol. 2017 Dec 22. pii: 4772556. doi: 10.1093.
    PubMed     Text format     Abstract available


  225. GUIHOT A, Marcelin AG, Massiani MA, Samri A, et al
    Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer.
    Ann Oncol. 2017 Dec 1. pii: 4677259. doi: 10.1093.
    PubMed     Text format    


  226. BI N, Liang J, Wang L
    Response to 'Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest'.
    Ann Oncol. 2017;28:3101-3103.
    PubMed     Text format    


    November 2017
  227. YOSHIDA H, Kim YH, Ozasa H, Nagai H, et al
    Nivolumab in non-small cell lung cancer with EGFR mutation.
    Ann Oncol. 2017 Nov 17. doi: 10.1093.
    PubMed     Text format    


  228. EK L, Gezelius E, Bergman B, Bendahl PO, et al
    Randomized Phase III Trial of Low Molecular Weight Heparin Enoxaparin in Addition to Standard Treatment in Small Cell Lung Cancer: the RASTEN Trial.
    Ann Oncol. 2017 Nov 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  229. HAYASHI H, Mitsudomi T
    S-1 as an option for second-line treatment of NSCLC. Is the 'East Side Story' applicable in the West?
    Ann Oncol. 2017;28:2627-2629.
    PubMed     Text format    


    October 2017
  230. OTSUBO K, Seki N, Nakanishi Y, Okamoto I, et al
    Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small cell lung cancer.
    Ann Oncol. 2017 Oct 23. doi: 10.1093.
    PubMed     Text format    


  231. ULAHANNAN D, Khalifa J, Faivre-Finn C, Lee SM, et al
    Emerging treatment paradigms in brain metastasis in non-small cell lung cancer: an overview of the current landscape and challenges ahead.
    Ann Oncol. 2017 Oct 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  232. SORIA JC, Fulop A, Maciel C, Fischer JR, et al
    SELECT-2: a Phase II, double-blind, randomised, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment for patients with advanced or metastatic non-small cell lung cancer.
    Ann Oncol. 2017 Oct 3. doi: 10.1093.
    PubMed     Text format     Abstract available


  233. MARTINEZ-MARTI A, Felip E, Matito J, Mereu E, et al
    Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
    Ann Oncol. 2017;28:2451-2457.
    PubMed     Text format     Abstract available


  234. CALVO E, Moreno V, Flynn M, Holgado E, et al
    Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.
    Ann Oncol. 2017;28:2559-2566.
    PubMed     Text format     Abstract available


    September 2017
  235. NOKIHARA H, Lu S, Mok TSK, Nakagawa K, et al
    Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).
    Ann Oncol. 2017 Sep 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  236. WEBER S, Wolkewitz M, Schumacher M
    Analyzing the impact of Depth of Response on Survival in patients with metastatic non-small cell lung cancer.
    Ann Oncol. 2017 Sep 26. doi: 10.1093.
    PubMed     Text format    


  237. ARGIRIS A, Lee JW, Stevenson J, Sulecki MG, et al
    Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3508).
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  238. BUTTERBAUGH ST, Patel R, Romond EH, Mathew A, et al
    Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: To continue or not to continue.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format    


  239. KATAKAMI N, Felip E, Spigel DR, Kim JH, et al
    A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.
    Ann Oncol. 2017;28:2241-2247.
    PubMed     Text format     Abstract available


  240. ITO M, Fujiwara S, Fujimoto D, Mori R, et al
    Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient.
    Ann Oncol. 2017;28:2318-2319.
    PubMed     Text format    


  241. MANAPOV F, Eze C
    Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest.
    Ann Oncol. 2017;28:2319-2320.
    PubMed     Text format    


    August 2017
  242. SAAD ED, Buyse M
    Editorial on "Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small cell lung cancer treated with a targeted therapy or immunotherapy".
    Ann Oncol. 2017 Aug 23. doi: 10.1093.
    PubMed     Text format    


  243. KOLLER M, Hjermstad MJ, Tomaszewski KA, Tomaszewska IM, et al
    An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients.
    Ann Oncol. 2017 Aug 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  244. MAENO K, Fukuda S, Oguri T, Niimi A, et al
    Nivolumab-induced asthma in a patient with non-small cell lung cancer.
    Ann Oncol. 2017 Aug 22. doi: 10.1093.
    PubMed     Text format    


  245. MCCOACH CE, Blumenthal GM, Zhang L, Myers A, et al
    Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small cell lung cancer treated with a targeted therapy or immunotherapy.
    Ann Oncol. 2017 Aug 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  246. CURIONI-FONTECEDRO A, Ickenberg C, Franzen D, Rogler G, et al
    Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab.
    Ann Oncol. 2017;28:2040-2041.
    PubMed     Text format    


    July 2017
  247. LEDUC C, Merlio JP, Besse B, Blons H, et al
    Clinical and molecular characteristics of non-small cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.
    Ann Oncol. 2017 Jul 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  248. HENTRICH M, Schipek-Voigt K, Jager H, Schulz S, et al
    Nivolumab in HIV-related non-small-cell lung cancer.
    Ann Oncol. 2017 Jul 6. doi: 10.1093.
    PubMed     Text format    



  249. Appendix 8: Metastatic non-small-cell lung cancer (2): eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
    Ann Oncol. 2017;28.
    PubMed     Text format    



  250. Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
    Ann Oncol. 2017;28.
    PubMed     Text format    


  251. POSTMUS PE, Kerr KM, Oudkerk M, Senan S, et al
    Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2017;28.
    PubMed     Text format    


  252. BOLAND JM, Mansfield AS, Roden AC
    Pulmonary sarcomatoid carcinoma-a new hope.
    Ann Oncol. 2017;28:1417-1418.
    PubMed     Text format    


  253. PECUCHET N, Vieira T, Rabbe N, Antoine M, et al
    Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities.
    Ann Oncol. 2017;28:1597-1604.
    PubMed     Text format     Abstract available


  254. LESAFFRE E, Edelman MJ, Hanna NH, Park K, et al
    Statistical controversies in clinical research: futility analyses in oncology-lessons on potential pitfalls from a randomized controlled trial.
    Ann Oncol. 2017;28:1419-1426.
    PubMed     Text format     Abstract available


    June 2017
  255. TOMITA Y, Sueta D, Kakiuchi Y, Saeki S, et al
    Acute Coronary Syndrome as a Possible Immune-Related Adverse Event in a Lung Cancer Patient Achieving a Complete Response to Anti-PD-1 Immune Checkpoint Antibody.
    Ann Oncol. 2017 Jun 23. doi: 10.1093.
    PubMed     Text format    


  256. LINDSAY CR, Faugeroux V, Michiels S, Pailler E, et al
    A Prospective Examination of Circulating Tumor Cell Profiles in Non-Small Cell Lung Cancer Molecular Subgroups.
    Ann Oncol. 2017 Jun 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  257. DEVARAKONDA S, Govindan R
    TRAC(ERx)-ing Lung Cancer Evolution.
    Ann Oncol. 2017 Jun 19. doi: 10.1093.
    PubMed     Text format    


  258. SANMAMED MF, Perez-Gracia JL, Schalper KA, Fusco JP, et al
    Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients.
    Ann Oncol. 2017 Jun 8. doi: 10.1093.
    PubMed     Text format     Abstract available


  259. DURUISSEAUX M, Mc Leer-Florin A, Moro-Sibilot D, Cadranel J, et al
    Are ALK rearrangement variants promising predictive biomarker of ALK tyrosine kinase inhibitors efficacy?
    Ann Oncol. 2017;28:1401.
    PubMed     Text format    


  260. KIM HR, Kang HN, Shim HS, Kim EY, et al
    Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.
    Ann Oncol. 2017;28:1250-1259.
    PubMed     Text format     Abstract available


    May 2017
  261. CHRISTOPOULOS P, Engel-Riedel W, Grohe C, Kropf-Sanchen C, et al
    Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.
    Ann Oncol. 2017 May 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  262. CURROW D, Temel JS, Abernethy A, Milanowski J, et al
    ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with cachexia.
    Ann Oncol. 2017 May 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  263. GUBERINA M, Eberhardt W, Stuschke M, Gauler T, et al
    Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial.
    Ann Oncol. 2017;28:1084-1089.
    PubMed     Text format     Abstract available


  264. ZHANG L, Ye Y, Tu H, Hildebrandt MA, et al
    MicroRNA-related genetic variants in iron regulatory genes, dietary iron intake, microRNAs and lung cancer risk.
    Ann Oncol. 2017;28:1124-1129.
    PubMed     Text format     Abstract available


  265. BESSE B, Mazieres J, Ribassin-Majed L, Barlesi F, et al
    Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.
    Ann Oncol. 2017;28:1078-1083.
    PubMed     Text format     Abstract available


    April 2017
  266. DHILLON HM, Bell ML, van der Ploeg HP, Turner JD, et al
    Impact of Physical Activity on Fatigue and Quality of Life in People with Advanced Lung Cancer: a Randomised Controlled Trial.
    Ann Oncol. 2017 Apr 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  267. HARATANI K, Hayashi H, Tanaka T, Kaneda H, et al
    Tumor Immune Microenvironment and Nivolumab Efficacy in EGFR Mutation-Positive Non-Small Cell Lung Cancer Based on T790M Status after Disease Progression During EGFR-TKI Treatment.
    Ann Oncol. 2017 Apr 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  268. SEO S, Woo CG, Lee DH, Choi J, et al
    The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small cell lung cancer.
    Ann Oncol. 2017 Apr 12. doi: 10.1093.
    PubMed     Text format    


  269. FERRONIKA P, van den Bos H, Taudt A, Spierings DCJ, et al
    Copy number alterations assessed at the single-cell level revealed mono- and polyclonal seeding patterns of distant metastasis in a small cell lung cancer patient.
    Ann Oncol. 2017 Apr 11. doi: 10.1093.
    PubMed     Text format    


  270. ZHANG Y, Zhang L, Li R, Chang DW, et al
    Genetic variations in cancer-related significantly mutated genes and lung cancer susceptibility.
    Ann Oncol. 2017 Apr 5. doi: 10.1093.
    PubMed     Text format     Abstract available


  271. REMON J, Caramella C, Jovelet C, Lacroix L, et al
    Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.
    Ann Oncol. 2017;28:784-790.
    PubMed     Text format     Abstract available


    March 2017
  272. KATAOKA Y, Ebi N, Fujimoto D, Hara S, et al
    Prior radiotherapy does not predict nivolumab response in non-small cell lung cancer: a retrospective cohort study.
    Ann Oncol. 2017 Mar 20. doi: 10.1093.
    PubMed     Text format    


  273. KIM ST, Kim SY, Klempner SJ, Yoon J, et al
    Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
    Ann Oncol. 2017;28:547-554.
    PubMed     Text format     Abstract available


  274. CHANDRANI P, Prabhash K, Prasad R, Sethunath V, et al
    Drug-sensitive FGFR3 mutations in lung adenocarcinoma.
    Ann Oncol. 2017;28:597-603.
    PubMed     Text format     Abstract available


    February 2017
  275. ZOU T, Awad MM
    More valuable than platinum: first-line pembrolizumab in advanced stage non-small cell lung cancer.
    Ann Oncol. 2017 Feb 27. doi: 10.1093.
    PubMed     Text format    


  276. GUBERINA M, Eberhardt W, Stuschke M, Gauler T, et al
    Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomised trial.
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  277. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2017, with focus on lung cancer.
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  278. PAZ-ARES L, Tan EH, O'Byrne K, Zhang L, et al
    Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
    Ann Oncol. 2017;28:270-277.
    PubMed     Text format     Abstract available


  279. YOSHIOKA H, Katakami N, Okamoto H, Iwamoto Y, et al
    A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer.
    Ann Oncol. 2017;28:285-291.
    PubMed     Text format     Abstract available


  280. REMON J, Soria JC
    Improving brain penetration of kinase inhibitors in lung cancer patients with oncogene dependency.
    Ann Oncol. 2017;28:196-198.
    PubMed     Text format    


  281. YANG TO, Cairns BJ, Reeves GK, Green J, et al
    Cancer risk among 21st century blood transfusion recipients.
    Ann Oncol. 2017;28:393-399.
    PubMed     Text format     Abstract available


  282. YU HA, Sima C, Feldman D, Liu LL, et al
    Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.
    Ann Oncol. 2017;28:278-284.
    PubMed     Text format     Abstract available


    January 2017
  283. KADARA H, Choi M, Zhang J, Parra ER, et al
    Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
    Ann Oncol. 2017;28:75-82.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: